Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
probiotic complex
- Development stage
- Phase 2
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Nasogastric Tube
01
Overview
Probiotic complex refers to a formulation containing multiple strains of beneficial microorganisms, typically bacteria, intended to confer health benefits to the host. These complexes are often used as dietary supplements to modulate the gut microbiota. The mechanism of action involves introducing live microorganisms that can colonize the gastrointestinal tract, interact with the host's immune system, produce beneficial metabolites, and compete with pathogenic bacteria, thereby contributing to the balance and health of the intestinal flora. Specific strains found in such complexes include Bifidobacteria animalis HN019, Bacillus butyricosus rhamnosus HN001, Bifidobacteria animalis Bb-12, Lactobacillus acidophilus NCFM, and Bifidobacteria brevis M-16V.
- Brand names
- VSL#3VisbiomeVivomixx
- Other names
- Multi-strain probioticsProbiotic cocktailMixed probiotics
02
Targets
PRR (Pattern recognition receptors)CELA2A (Chymotrypsin-like elastase family member 2A)
Beyond the preview
Go deeper on probiotic complex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on probiotic complex.